Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas: An International Multicenter Study of 318 Cases.
Journal
The Journal of bone and joint surgery. American volume
ISSN: 1535-1386
Titre abrégé: J Bone Joint Surg Am
Pays: United States
ID NLM: 0014030
Informations de publication
Date de publication:
07 10 2020
07 10 2020
Historique:
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
20
4
2021
Statut:
ppublish
Résumé
Osteofibrous dysplasia-like adamantinoma (OFD-AD) and classic adamantinoma (AD) are rare, neoplastic diseases with only limited data supporting current treatment protocols. We believe that our retrospective multicenter cohort study is the largest analysis of patients with adamantinoma to date. The primary purpose of this study was to describe the disease characteristics and evaluate the oncological outcomes. The secondary purpose was to identify risk factors for local recurrence after surgical treatment and propose treatment guidelines. Three hundred and eighteen confirmed cases of OFD-AD and AD for which primary treatment was carried out between 1985 and 2015 were submitted by 22 tertiary bone tumor centers. Proposed clinical risk factors for local recurrence such as size, type, and margins were analyzed using univariable and multivariate Cox regression analysis. Of the 318 cases, 128 were OFD-AD and 190 were AD. The mean age at diagnosis was 17 years (median, 14.5 years) for OFD-AD and 32 years (median, 28 years) for AD; 53% of the patients were female. The mean tumor size in the OFD-AD and AD groups combined was 7.8 cm, measured histologically. Sixteen percent of the patients sustained a pathological fracture prior to treatment. Local recurrence was recorded in 22% of the OFD-AD cases and 24% of the AD cases. None of the recurrences in the OFD-AD group progressed to AD. Metastatic disease was found in 18% of the AD cases and fatal disease, in 11% of the AD cases. No metastatic or fatal disease was reported in the OFD-AD group. Multivariate Cox regression analysis demonstrated that uncontaminated resection margins (hazard ratio [HR] = 0.164, 95% confidence interval [CI] = 0.092 to 0.290, p < 0.001), pathological fracture (HR = 1.968, 95% CI = 1.076 to 3.600, p = 0.028), and sex (female versus male: HR = 0.535, 95% CI = 0.300 to 0.952, p = 0.033) impacted the risk of local recurrence. OFD-AD and AD are parts of a disease spectrum but should be regarded as different entities. Our results support reclassification of OFD-AD into the intermediate locally aggressive category, based on the local recurrence rate of 22% and absence of metastases. In our study, metastatic disease was restricted to the AD group (an 18% rate). We advocate wide resection with uncontaminated margins including bone and involved periosteum for both OFD-AD and AD. Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
Sections du résumé
BACKGROUND
Osteofibrous dysplasia-like adamantinoma (OFD-AD) and classic adamantinoma (AD) are rare, neoplastic diseases with only limited data supporting current treatment protocols. We believe that our retrospective multicenter cohort study is the largest analysis of patients with adamantinoma to date. The primary purpose of this study was to describe the disease characteristics and evaluate the oncological outcomes. The secondary purpose was to identify risk factors for local recurrence after surgical treatment and propose treatment guidelines.
METHODS
Three hundred and eighteen confirmed cases of OFD-AD and AD for which primary treatment was carried out between 1985 and 2015 were submitted by 22 tertiary bone tumor centers. Proposed clinical risk factors for local recurrence such as size, type, and margins were analyzed using univariable and multivariate Cox regression analysis.
RESULTS
Of the 318 cases, 128 were OFD-AD and 190 were AD. The mean age at diagnosis was 17 years (median, 14.5 years) for OFD-AD and 32 years (median, 28 years) for AD; 53% of the patients were female. The mean tumor size in the OFD-AD and AD groups combined was 7.8 cm, measured histologically. Sixteen percent of the patients sustained a pathological fracture prior to treatment. Local recurrence was recorded in 22% of the OFD-AD cases and 24% of the AD cases. None of the recurrences in the OFD-AD group progressed to AD. Metastatic disease was found in 18% of the AD cases and fatal disease, in 11% of the AD cases. No metastatic or fatal disease was reported in the OFD-AD group. Multivariate Cox regression analysis demonstrated that uncontaminated resection margins (hazard ratio [HR] = 0.164, 95% confidence interval [CI] = 0.092 to 0.290, p < 0.001), pathological fracture (HR = 1.968, 95% CI = 1.076 to 3.600, p = 0.028), and sex (female versus male: HR = 0.535, 95% CI = 0.300 to 0.952, p = 0.033) impacted the risk of local recurrence.
CONCLUSIONS
OFD-AD and AD are parts of a disease spectrum but should be regarded as different entities. Our results support reclassification of OFD-AD into the intermediate locally aggressive category, based on the local recurrence rate of 22% and absence of metastases. In our study, metastatic disease was restricted to the AD group (an 18% rate). We advocate wide resection with uncontaminated margins including bone and involved periosteum for both OFD-AD and AD.
LEVEL OF EVIDENCE
Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
Identifiants
pubmed: 33027124
doi: 10.2106/JBJS.19.01056
pii: 00004623-202010070-00006
pmc: PMC8569856
mid: NIHMS1726352
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1703-1713Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Investigateurs
Reinhard Windhager
(R)
Guido Scoccianti
(G)
Eric Mascard
(E)
Anthony Griffin
(A)
Zhiping Deng
(Z)
Andreas Krieg
(A)
Olivera Calukovic
(O)
Rianne Schoo
(R)
Robert van der Wal
(R)
Références
Diagn Pathol. 2008 Feb 15;3:8
pubmed: 18279517
J Surg Oncol. 2018 Dec;118(7):1150-1154
pubmed: 30332521
J Surg Oncol. 2006 Apr 1;93(5):429-33
pubmed: 16550582
Orthop Traumatol Surg Res. 2016 Nov;102(7):925-932
pubmed: 27745864
J Am Acad Orthop Surg. 2010 Jun;18(6):358-66
pubmed: 20511441
Cancer. 1989 Aug 1;64(3):730-7
pubmed: 2743266
Am J Surg Pathol. 1981 Sep;5(6):533-42
pubmed: 7325273
Pediatr Radiol. 2006 Oct;36(10):1068-74
pubmed: 16906392
J Bone Joint Surg Am. 1994 Oct;76(10):1482-99
pubmed: 7929496
Pathol Oncol Res. 2009 Jun;15(2):209-16
pubmed: 19048403
J Bone Joint Surg Am. 1954 Jul;36-A(4):704-20
pubmed: 13174600
Clin Orthop Relat Res. 1986 Mar;(204):215-37
pubmed: 3514033
Hum Pathol. 1998 Aug;29(8):809-14
pubmed: 9712421
Acta Ortop Bras. 2018;26(4):252-254
pubmed: 30210255
J Bone Joint Surg Am. 1975 Mar;57(2):148-54
pubmed: 1112840
Am J Surg Pathol. 1993 Dec;17(12):1225-33
pubmed: 7694513
J Bone Joint Surg Am. 2000 Aug;82(8):1122-31
pubmed: 10954102
Cancer. 1989 Dec 1;64(11):2319-34
pubmed: 2804923
Am J Clin Oncol. 1994 Apr;17(2):157-9
pubmed: 7511328
Am J Surg Pathol. 2008 Mar;32(3):363-76
pubmed: 18300815
Skeletal Radiol. 2003 May;32(5):245-58
pubmed: 12679847
Tohoku J Exp Med. 2006 May;209(1):53-9
pubmed: 16636523
Hum Pathol. 1977 Mar;8(2):141-53
pubmed: 852865
Bone Joint J. 2017 Mar;99-B(3):409-416
pubmed: 28249983
Pathol Res Pract. 1995 Mar;191(2):112-20
pubmed: 7567680